Localized expression of tenascin in systemic sclerosis-associated pulmonary fibrosis and its regulation by insulin-like growth factor binding protein 3.

OBJECTIVE To determine the role of insulin-like growth factor binding protein 3 (IGFBP-3) in mediating the effects of transforming growth factor β (TGFβ) on tenascin-C (TN-C) production and to assess the levels of TN-C in vivo in patients with systemic sclerosis (SSc)-associated pulmonary fibrosis. METHODS Human primary lung fibroblasts were stimulated with TGFβ or IGFBP-3 in the presence or absence of specific small interfering RNAs and chemical inhibitors of the signaling cascade. TN-C levels in lung tissue specimens obtained from patients with SSc-associated pulmonary fibrosis were assessed using immunohistochemical analysis and were compared with the levels in specimens obtained from normal donors. TN-C levels were quantified in sera from normal donors and patients with SSc with or without pulmonary fibrosis, using an enzyme-linked immunosorbent assay. RESULTS IGFBP-3 mediated the induction of TN-C by TGFβ. Direct induction of TN-C by IGFBP-3 occurred in a p38 MAP kinase-dependent manner. TN-C levels were abundant in lung tissues from patients with SSc and were localized to subepithelial layers of the distal airways. No TN-C was detectable around the proximal airways. Patients with SSc-associated pulmonary fibrosis had significantly higher levels of circulating TN-C compared with SSc patients without pulmonary fibrosis. Longitudinal samples obtained from patients with SSc before and after the onset of pulmonary fibrosis showed increased levels of TN-C after the onset of pulmonary fibrosis. CONCLUSION IGFBP-3, which is overexpressed in fibrotic lungs, induces production of TN-C by subepithelial fibroblasts. The increased lung tissue levels of TN-C parallel the levels detected in the sera of SSc patients with pulmonary fibrosis, suggesting that TN-C may be a useful biomarker for SSc-related pulmonary fibrosis.

[1]  S. Young,et al.  Induction of tenascin in rat lungs undergoing bleomycin-induced pulmonary fibrosis. , 1998, American journal of physiology. Lung cellular and molecular physiology.

[2]  J. Rosenbloom,et al.  IGFBP-3 mediates TGF-beta1-induced cell growth in human airway smooth muscle cells. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[3]  B. Willis,et al.  Epithelial origin of myofibroblasts during fibrosis in the lung. , 2006, Proceedings of the American Thoracic Society.

[4]  I. Virtanen,et al.  Tenascin is increased in airway basement membrane of asthmatics and decreased by an inhaled steroid. , 1997, American journal of respiratory and critical care medicine.

[5]  J. Pilewski,et al.  Insulin-like growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmonary fibrosis and contribute to extracellular matrix deposition. , 2005, The American journal of pathology.

[6]  F. Rödel,et al.  Transforming growth factor beta 1 dependent regulation of Tenascin-C in radiation impaired wound healing. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  D. Lamb,et al.  Tenascin immunoreactivity in cryptogenic fibrosing alveolitis , 1995, The Journal of pathology.

[8]  Y. Soini,et al.  Tenascin immunoreactivity as a prognostic marker in usual interstitial pneumonia. , 1996, American journal of respiratory and critical care medicine.

[9]  T. Sakakura,et al.  Nodular Scleroderma: Focally Increased Tenascin Expression Differing from That in the Surrounding Scleroderma Skin , 1995, The Journal of dermatology.

[10]  F. Verrecchia,et al.  Identification of Novel TGF-β/Smad Gene Targets in Dermal Fibroblasts using a Combined cDNA Microarray/Promoter Transactivation Approach* , 2001, The Journal of Biological Chemistry.

[11]  W. Halfter,et al.  Induction of tenascin in healing wounds , 1988, The Journal of cell biology.

[12]  R. Domsic,et al.  Anti-U11/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis. , 2009, Arthritis and rheumatism.

[13]  James F. Fries,et al.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. , 1980, Arthritis and rheumatism.

[14]  R. Mason,et al.  Immunolocalization of SPARC, tenascin, and thrombospondin in pulmonary fibrosis. , 1995, The American journal of pathology.

[15]  E. Friedman,et al.  Igfbp‐3 mediates TGFβ1 proliferative response in colon cancer cells , 2000 .

[16]  B. Stripp,et al.  Reparative capacity of airway epithelium impacts deposition and remodeling of extracellular matrix. , 2009, American journal of respiratory cell and molecular biology.

[17]  Shigeki,et al.  Tenascin: cDNA cloning and induction by TGF‐beta. , 1988, The EMBO journal.

[18]  S. Wenzel,et al.  Role of insulin-like growth factor binding protein-3 in allergic airway remodeling. , 2009, American journal of respiratory and critical care medicine.

[19]  L. Zardi,et al.  Different Susceptibility of Small and Large Human Tenascin-C Isoforms to Degradation by Matrix Metalloproteinases (*) , 1995, The Journal of Biological Chemistry.

[20]  Y. Soini,et al.  Tenascin is Increased in Epithelial Lining Fluid in Fibrotic Lung Disorders , 1998, Lung.

[21]  J. Ortonne,et al.  Increased expression of tenascin in the dermis in scleroderma , 1992, The British journal of dermatology.

[22]  M. Chiquet,et al.  Induction of tenascin-C by cyclic tensile strain versus growth factors: distinct contributions by Rho/ROCK and MAPK signaling pathways. , 2004, Biochimica et biophysica acta.

[23]  H. Mukae,et al.  Elevated levels of tenascin-C in patients with cryptogenic organizing pneumonia. , 2009, Internal medicine.

[24]  K. Midwood,et al.  Regulation of fibroblast migration by tenascin-C. , 2007, Biochemical Society transactions.

[25]  G. Panayotou,et al.  Tenascin: a modulator of cell growth. , 1992, European journal of biochemistry.

[26]  R. Rosenfeld,et al.  Transforming Growth Factor- β-induced Cell Growth Inhibition in Human Breast Cancer Cells Is Mediated through Insulin-like Growth Factor-binding Protein-3 Action (*) , 1995, The Journal of Biological Chemistry.

[27]  T. Medsger,et al.  Severe organ involvement in systemic sclerosis with diffuse scleroderma. , 2000, Arthritis and rheumatism.

[28]  Qihe Xu,et al.  In vitro models of TGF-beta-induced fibrosis suitable for high-throughput screening of antifibrotic agents. , 2007, American journal of physiology. Renal physiology.

[29]  A. Masi Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[30]  A. El-Karef,et al.  Deficiency of tenascin‐C attenuates liver fibrosis in immune‐mediated chronic hepatitis in mice , 2007, The Journal of pathology.

[31]  M. Hiroe,et al.  Interaction between cell and extracellular matrix in heart disease: multiple roles of tenascin-C in tissue remodeling. , 2004, Histology and histopathology.